Advertisement

Current Hypertension Reports

, Volume 12, Issue 2, pp 99–104 | Cite as

Central Adiposity, Systemic Inflammation, and the Metabolic Syndrome

  • Carrie M. Elks
  • Joseph Francis
Article

Abstract

Metabolic syndrome (MetS) is a constellation of metabolic derangements and underlying factors that significantly increases the risk for developing type 2 diabetes and cardiovascular diseases. MetS is a low-grade inflammatory condition, with systemic inflammation and inflammation of central abdominal fat as contributors. Systemic inflammation in MetS is thought to involve C-reactive protein and some proinflammatory cytokines; the nuclear factor-κB pathway also is believed to play a role. Inflammation of central adipose tissue leads to adipokine production, followed by secretion of adipokines into the general circulation to contribute to the overall inflammatory condition. The molecular mechanisms that contribute to this inflammation are still somewhat unclear, but several serine/threonine kinases are known to be involved. Dietary components may also contribute to central adiposity and the inflammation seen in MetS.

Keywords

Inflammation Adipokines Oxidative stress Metabolic syndrome 

Notes

Disclosure

No potential conflicts of interest relevant to this article were reported.

References

Papers of particular interest, published recently, have been highlighted as: • Of importance •• Of major importance

  1. 1.
    Alberti KGMM, Eckel RH, Grundy SM, et al.: Harmonizing the metabolic syndrome: a joint interim statement of the International Diabetes Federation Task Force on Epidemiology and Prevention; National Heart, Lung, and Blood Institute; American Heart Association; World Heart Federation; International Atherosclerosis Society; and International Association for the Study of Obesity. Circulation 2009, 120:1640–1645.CrossRefPubMedGoogle Scholar
  2. 2.
    Bray GA, Clearfield MB, Fintel DJ, et al.: Overweight and obesity: the pathogenesis of cardiometabolic risk. Clin Cornerstone 2009, 9:30–42.CrossRefPubMedGoogle Scholar
  3. 3.
    Bray G, Bellanger T: Epidemiology, trends, and morbidities of obesity and the metabolic syndrome. Endocrine 2006, 29:109–117.CrossRefPubMedGoogle Scholar
  4. 4.
    Blaha MJ, Gebretsadik T, Shintani A, et al.: Waist circumference, not the metabolic syndrome, predicts glucose deterioration in type 2 diabetes. Obesity 2008, 16:869–874.PubMedGoogle Scholar
  5. 5.
    Bray GA, Champagne CM: Obesity and the metabolic syndrome: implications for dietetics practitioners. J Am Diet Assoc 2004, 104:86–89.CrossRefPubMedGoogle Scholar
  6. 6.
    Kannel WB, Cupples LA, Ramaswami R, et al.: Regional obesity and risk of cardiovascular disease; the Framingham Study. J Clin Epidemiol 1991, 44:183–190.CrossRefPubMedGoogle Scholar
  7. 7.
    Anfossi G, Russo I, Trovati M: Platelet dysfunction in central obesity. Nutr Metab Cardiovasc Dis 2009, 19:440–449.CrossRefPubMedGoogle Scholar
  8. 8.
    Bourlier V, Bouloumie A: Role of macrophage tissue infiltration in obesity and insulin resistance. Diabetes Metab 2009, 35:251–260.CrossRefPubMedGoogle Scholar
  9. 9.
    Maury E, Brichard SM: Adipokine dysregulation, adipose tissue inflammation and metabolic syndrome. Mol Cell Endocrinol 2010, 314:1–16.CrossRefPubMedGoogle Scholar
  10. 10.
    Shoelson SE, Lee J, Goldfine AB: Inflammation and insulin resistance. J Clin Invest 2006, 116:1793–1801.CrossRefPubMedGoogle Scholar
  11. 11.
    Yudkin JS, Juhan-Vague I, Hawe E, et al.: Low-grade inflammation may play a role in the etiology of the metabolic syndrome in patients with coronary heart disease: the HIFMECH study. Metabolism 2004, 53:852–857.CrossRefPubMedGoogle Scholar
  12. 12.
    Petersen AMW, Pedersen BK: The anti-inflammatory effect of exercise. J Appl Physiol 2005, 98:1154–1162.CrossRefPubMedGoogle Scholar
  13. 13.
    Guldiken S, Demir M, Arikan E, et al.: The levels of circulating markers of atherosclerosis and inflammation in subjects with different degrees of body mass index: soluble CD40 ligand and high-sensitivity C-reactive protein. Thromb Res 2007, 119:79–84.CrossRefPubMedGoogle Scholar
  14. 14.
    Nakamura H, Ito H, Egami Y, et al.: Waist circumference is the main determinant of elevated C-reactive protein in metabolic syndrome. Diabetes Res Clin Pract 2008, 79:330–336.CrossRefPubMedGoogle Scholar
  15. 15.
    Elks CM, Mariappan N, Haque M, et al.: Chronic NF-κB blockade reduces cytosolic and mitochondrial oxidative stress and attenuates renal injury and hypertension in SHR. Am J Physiol Renal Physiol 2009, 296:F298–F305.CrossRefPubMedGoogle Scholar
  16. 16.
    Ebenezer PJ, Mariappan N, Elks CM, et al.: Effects of pyrrolidine dithiocarbamate on high-fat diet-induced metabolic and renal alterations in rats. Life Sci 2009, 85:357–364.CrossRefPubMedGoogle Scholar
  17. 17.
    Ebenezer PJ, Mariappan N, Elks CM, et al.: Diet-induced renal changes in Zucker rats are ameliorated by the superoxide dismutase mimetic TEMPOL. Obesity 2009, 17:1994–2002.CrossRefPubMedGoogle Scholar
  18. 18.
    Bourlier V, Zakaroff-Girard A, Miranville A, et al.: Remodeling phenotype of human subcutaneous adipose tissue macrophages. Circulation 2008, 117:806–815.CrossRefPubMedGoogle Scholar
  19. 19.
    Henegar C, Tordjman J, Achard V, et al.: Adipose tissue transcriptomic signature highlights the pathological relevance of extracellular matrix in human obesity. Genome Biol 2008, 9:R14.CrossRefPubMedGoogle Scholar
  20. 20.
    Maury E, Ehala-Aleksejev K, Guiot Y, et al.: Adipokines oversecreted by omental adipose tissue in human obesity. Am J Physiol Endocrinol Metab 2007, 293:E656–E665.CrossRefPubMedGoogle Scholar
  21. 21.
    Wisse BE: The inflammatory syndrome: the role of adipose tissue cytokines in metabolic disorders linked to obesity. J Am Soc Nephrol 2004, 15:2792–2800.CrossRefPubMedGoogle Scholar
  22. 22.
    Jernas M, Palming J, Sjoholm K, et al.: Separation of human adipocytes by size: hypertrophic fat cells display distinct gene expression. FASEB J 2006, 20:1540–1542.CrossRefPubMedGoogle Scholar
  23. 23.
    Skurk T, Alberti-Huber C, Herder C, et al.: Relationship between adipocyte size and adipokine expression and secretion. J Clin Endocrinol Metab 2007, 92:1023–1033.CrossRefPubMedGoogle Scholar
  24. 24.
    Weisberg SP, McCann D, Desai M, et al.: Obesity is associated with macrophage accumulation in adipose tissue. J Clin Invest 2003, 112:1796–1808.PubMedGoogle Scholar
  25. 25.
    Berg AH, Lin Y, Lisanti MP, et al.: Adipocyte differentiation induces dynamic changes in NFκB expression and activity. Am J Physiol Endocrinol Metab 2004, 287:E1178–E1188.CrossRefPubMedGoogle Scholar
  26. 26.
    •• Maury E, Noel L, Detry R, et al.: In vitro hyperresponsiveness to tumor necrosis factor-α contributes to adipokine dysregulation in omental adipocytes of obese subjects. J Clin Endocrinol Metab 2009, 94:1393–1400. Using primary cultures of omental adipocytes from obese and nonobese patients, the authors examined adipokine production and found that omental adipocytes from obese patients overproduced adipokines. This effect was diminished by immunoneutralization of TNF-α and was found to be mediated through overactivity of the NF-κB pathway. CrossRefPubMedGoogle Scholar
  27. 27.
    Sengenès C, Miranville A, Lolmède K, et al.: The role of endothelial cells in inflamed adipose tissue. J Intern Med 2007, 262:415–421.CrossRefPubMedGoogle Scholar
  28. 28.
    Wang B, Wood I, Trayhurn P: Dysregulation of the expression and secretion of inflammation-related adipokines by hypoxia in human adipocytes. Pflügers Arch 2007, 455:479–492.CrossRefPubMedGoogle Scholar
  29. 29.
    Shi H, Kokoeva MV, Inouye K, et al.: TLR4 links innate immunity and fatty acid–induced insulin resistance. J Clin Invest 2006, 116:3015–3025.CrossRefPubMedGoogle Scholar
  30. 30.
    Suganami T, Mieda T, Itoh M, et al.: Attenuation of obesity-induced adipose tissue inflammation in C3H/HeJ mice carrying a Toll-like receptor 4 mutation. Biochem Biophys Res Commun 2007, 354:45–49.CrossRefPubMedGoogle Scholar
  31. 31.
    Ouchi N, Kihara S, Arita Y, et al.: Adiponectin, an adipocyte-derived plasma protein, inhibits endothelial NF-κB signaling through a cAMP-dependent pathway. Circulation 2000, 102:1296–1301.PubMedGoogle Scholar
  32. 32.
    Antuna-Puente B, Feve B, Fellahi S, et al.: Adipokines: the missing link between insulin resistance and obesity. Diabetes Metab 2008, 34:2–11.CrossRefPubMedGoogle Scholar
  33. 33.
    Ruge T, Lockton JA, Renstrom F, et al.: Acute hyperinsulinemia raises plasma interleukin-6 in both nondiabetic and type 2 diabetes mellitus subjects, and this effect is inversely associated with body mass index. Metabolism 2009, 58:860–866.CrossRefPubMedGoogle Scholar
  34. 34.
    Shin JH, Shin DW, Noh M: Interleukin-17A inhibits adipocyte differentiation in human mesenchymal stem cells and regulates pro-inflammatory responses in adipocytes. Biochem Pharmacol 2009, 77:1835–1844.CrossRefPubMedGoogle Scholar
  35. 35.
    Madsen EL, Bruun JM, Skogstrand K, et al.: Long-term weight loss decreases the nontraditional cardiovascular risk factors interleukin-18 and matrix metalloproteinase-9 in obese subjects. Metabolism 2009, 58:946–953.CrossRefPubMedGoogle Scholar
  36. 36.
    Kralisch S, Weise S, Sommer G, et al.: Interleukin-1β induces the novel adipokine chemerin in adipocytes in vitro. Regul Pept 2009, 154:102–106.CrossRefPubMedGoogle Scholar
  37. 37.
    Lagathu C, Yvan-Charvet L, Bastard JP, et al.: Long-term treatment with interleukin-1β induces insulin resistance in murine and human adipocytes. Diabetologia 2006, 49:2162–2173.CrossRefPubMedGoogle Scholar
  38. 38.
    Weise S, Kralisch S, Sommer G, et al.: Tissue inhibitor of metalloproteinase-1 mRNA production and protein secretion are induced by interleukin-1β in 3 T3-L1 adipocytes. J Endocrinol 2008, 198:169–174.CrossRefPubMedGoogle Scholar
  39. 39.
    Ahima RS, Flier JS: Leptin. Annu Rev Physiol 2000, 62:413–437.CrossRefPubMedGoogle Scholar
  40. 40.
    Yuan M, Konstantopoulos N, Lee J, et al.: Reversal of obesity-and diet-induced insulin resistance with salicylates or targeted disruption of Ikk β. Science 2001, 293:1673–1677.CrossRefPubMedGoogle Scholar
  41. 41.
    •• MacLaren R, Cui W, Simard S, et al.: Influence of obesity and insulin sensitivity on insulin signaling genes in human omental and subcutaneous adipose tissue. J Lipid Res 2008, 49:308–323. Subcutaneous and omental adipose tissue samples from nonobese, obese, insulin-sensitive, and insulin-resistant obese subjects were analyzed by microarray and confirmed by real-time PCR. In insulin-resistant obese tissues, insulin receptor substrate and its regulators JNK and IKK were upregulated (among other genes critical to adipocyte differentiation and adipokine production). The authors concluded that insulin resistance, not obesity, was associated with altered expression of insulin-signaling genes. CrossRefPubMedGoogle Scholar
  42. 42.
    Singh R, Wang Y, Xiang Y, et al.: Differential effects of JNK1 and JNK2 inhibition on murine steatohepatitis and insulin resistance. Hepatology 2009, 49:87–96.CrossRefPubMedGoogle Scholar
  43. 43.
    Buhl ES, Jessen N, Pold R, et al.: Long-term AICAR administration reduces metabolic disturbances and lowers blood pressure in rats displaying features of the insulin resistance syndrome. Diabetes 2002, 51:2199–2206.CrossRefPubMedGoogle Scholar
  44. 44.
    Li XN, Song J, Zhang L, et al.: Activation of the AMPK-FOXO3 pathway reduces fatty acid–induced increase in intracellular reactive oxygen species by upregulating thioredoxin. Diabetes 2009, 58:2246–2257.CrossRefPubMedGoogle Scholar
  45. 45.
    • Deng G, Long Y, Yu YR, et al.: Adiponectin directly improves endothelial dysfunction in obese rats through the AMPK-eNOS pathway. Int J Obes (Lond) 2010, 34(1):165–171. Sprague-Dawley rats were fed a regular or high-fat diet for 6 weeks and aortae were isolated and incubated with adiponectin. The investigators demonstrated increased endothelial dysfunction in rats fed a high-fat diet; the dysfunction improved with adiponectin incubation. Further, adiponectin increased the activity of eNOS through activating AMPK by stimulating its phosphorylation. CrossRefGoogle Scholar
  46. 46.
    Babio N, Bulló M, Basora J, et al.: Adherence to the Mediterranean diet and risk of metabolic syndrome and its components. Nutr Metab Cardiovasc Dis 2009, 19:563–570.CrossRefPubMedGoogle Scholar
  47. 47.
    Volek JS, Fernandez ML, Feinman RD, et al.: Dietary carbohydrate restriction induces a unique metabolic state positively affecting atherogenic dyslipidemia, fatty acid partitioning, and metabolic syndrome. Prog Lipid Res 2008, 47:307–318.CrossRefPubMedGoogle Scholar
  48. 48.
    •• Cavicchia PP, Steck SE, Hurley TG, et al.: A new dietary inflammatory index predicts interval changes in serum high-sensitivity C-reactive protein. J Nutr 2009, 139:2365–2372. The authors developed a dietary inflammatory index and used this index to examine 600 participants in a longitudinal study that controlled diet and measured CRP levels. The authors found that increases in the inflammatory index correlated with increases in CRP levels; they concluded that the inflammatory index was a good predictor of CRP and hence of inflammatory status. CrossRefPubMedGoogle Scholar
  49. 49.
    Aeberli I, Spinas GA, Lehmann R, et al.: Diet determines features of the metabolic syndrome in 6-to 14-year-old children. Int J Vitam Nutr Res 2009, 79:14–23.CrossRefPubMedGoogle Scholar

Copyright information

© Springer Science+Business Media, LLC 2010

Authors and Affiliations

  1. 1.Department of Comparative Biomedical SciencesLouisiana State University School of Veterinary MedicineBaton RougeUSA

Personalised recommendations